<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612581</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-MHB1-V200</org_study_id>
    <nct_id>NCT05612581</nct_id>
  </id_info>
  <brief_title>A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection</brief_title>
  <official_title>A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of&#xD;
      investigational candidate(s) and their combinations as potential treatments for adults with&#xD;
      chronic HBV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VIR-SHB1-V201 (STRIVE) Sub-Protocol A is a Phase 2 study under the PREVAIL platform trial.&#xD;
      This is a multi-center, open-label study designed to evaluate the safety and efficacy of&#xD;
      regimens containing VIR-3434, VIR-2218, PEG-IFNα, and NRTI in noncirrhotic adult participants&#xD;
      with chronic HBV infection that have not received prior NRTI or PEG-IFNα treatment.&#xD;
&#xD;
      VIR-SHB1-V202 (THRIVE) Sub-Protocol B is a Phase 2 study under the PREVAIL platform trial.&#xD;
      This is a multi-center open-label study designed to evaluate the safety and efficacy of&#xD;
      regimens containing VIR-3434 and NRTI with or without VIR-2218 in noncirrhotic adult&#xD;
      participants with low viral burden of chronic HBV infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2022</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>STRIVE and THRIVE: Proportion of participants achieving suppression of HBV DNA (&lt; LLOQ) with HBsAg loss (&lt; 0.05 IU/mL) at the end of treatment</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Proportion of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Proportion of participants with serum HBsAg ≤ 10 IU/mL at end of treatment</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Proportion of participants with serum HBsAg ≤ 10 IU/mL at 24 weeks post-end of treatment</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Serum HBsAg levels and change from baseline across timepoints in the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Serum HBsAg level at nadir during the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Time to achieve nadir of serum HBsAg during the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Time to achieve serum HBsAg loss (&lt; 0.05 IU/mL)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE and THRIVE: Proportion of participants with HBsAg loss with anti-HBs seroconversion at end of treatment and at 24 weeks post-end of treatment</measure>
    <time_frame>Up to 76 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Proportion of participants achieving sustained suppression of HBV DNA (&lt; LLOQ) with HBsAg loss (&lt; 0.05 IU/mL) after discontinuation of all treatment at 24 weeks and at the F48 Follow-Up visit</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Proportion of participants with HBsAg loss (&lt;0.05 IU/mL) at end of treatment and at 24 weeks post-end of treatment</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Proportion of participants achieving sustained suppression of HBV DNA (&lt; LLOQ) after discontinuation of all treatment at 24 weeks and at the F48 Follow-Up visit</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: For HBeAg-positive participants: proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Incidence and titers of anti-drug antibodies (ADA; if applicable) to VIR-3434</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Mean change in serum HBsAg level from baseline across timepoints in the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Proportion of participants achieving HBV DNA (&lt; LLOQ) across timepoints in the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STRIVE: Proportion of participants achieving ALT ≤ ULN across timepoints in the study</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Proportion of participants achieving sustained suppression of HBV DNA (&lt; LLOQ) with HBsAg loss (&lt; 0.05 IU/mL) after discontinuation of all treatment at 24 weeks and at 48 weeks</measure>
    <time_frame>Up to 92 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Proportion of participants achieving HBsAg loss (&lt; 0.05 IU/mL) at end of treatment and at 24 weeks post-end of treatment</measure>
    <time_frame>Up to 44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Proportion of participants achieving sustained suppression of HBV DNA (&lt; LLOQ) after discontinuation of all treatment at 24 weeks and at 48 weeks</measure>
    <time_frame>Up to 68 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Incidence and titers of ADA (if applicable) to VIR-3434</measure>
    <time_frame>Up to 92 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Mean change in serum HBsAg level from baseline across timepoints in the study</measure>
    <time_frame>Up to 92 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THRIVE: Proportion of participants achieving HBV DNA (&lt; LLOQ)</measure>
    <time_frame>Up to 92 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>STRIVE: Cohort 1a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STRIVE: Cohort 2a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STRIVE: Cohort 3a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THRIVE: Cohort 1b (VIR-3434 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-3434</intervention_name>
    <description>VIR-3434 given by subcutaneous injection</description>
    <arm_group_label>STRIVE: Cohort 1a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 2a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 3a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)</arm_group_label>
    <arm_group_label>THRIVE: Cohort 1b (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-2218</intervention_name>
    <description>VIR-2218 given by subcutaneous injection</description>
    <arm_group_label>STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)</arm_group_label>
    <arm_group_label>THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>TDF given orally</description>
    <arm_group_label>STRIVE: Cohort 1a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 2a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 3a (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
    <arm_group_label>STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)</arm_group_label>
    <arm_group_label>THRIVE: Cohort 1b (VIR-3434 + TDF)</arm_group_label>
    <arm_group_label>THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-IFNα</intervention_name>
    <description>PEG-IFNα given by subcutaneous injection</description>
    <arm_group_label>STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ages 18 or older&#xD;
&#xD;
          -  Chronic HBV infection for &gt;/= 6 months&#xD;
&#xD;
          -  Chronic HBV infection defined as a positive serum HBsAg, HBV DNA, or HBeAg on 2&#xD;
             occasions at least 6 months apart based on previous or current laboratory&#xD;
             documentation&#xD;
&#xD;
          -  STRIVE: HBeAg positive or negative, HBV DNA &gt; 2,000 IU/mL, ALT &gt; ULN and ≤ 5x ULN&#xD;
&#xD;
          -  THRIVE: Must be/have the following, within the 1-year period prior to screening: HBeAg&#xD;
             negative, HBV DNA ≤ 2,000 IU/mL, ALT ≤ ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant chronic or acute medical condition that makes the&#xD;
             participant unsuitable for participation&#xD;
&#xD;
          -  History of clinically significant liver disease from non-HBV etiology&#xD;
&#xD;
          -  History or current evidence of hepatic decompensation&#xD;
&#xD;
          -  Co-infection with human immunodeficiency virus (HIV), hepatitis A virus (HAV),&#xD;
             hepatitis C virus (HCV), hepatitis D virus (HDV) or hepatitis E virus (HEV).&#xD;
&#xD;
          -  History or clinical evidence of alcohol or drug abuse&#xD;
&#xD;
          -  STRIVE and THRIVE: Significant fibrosis or cirrhosis&#xD;
&#xD;
          -  STRIVE and THRIVE: History of immune complex disease&#xD;
&#xD;
          -  STRIVE and THRIVE: History of autoimmune disorder&#xD;
&#xD;
          -  STRIVE and THRIVE: History of allergic reactions, hypersensitivity, or intolerance to&#xD;
             monoclonal antibodies, antibody fragments, or any excipients of VIR-3434&#xD;
&#xD;
          -  STRIVE: Prior NRTI or PEG-IFN therapy&#xD;
&#xD;
          -  STRIVE: History of known contraindication to any interferon product&#xD;
&#xD;
          -  THRIVE: Prior NRTI therapy &lt; 24 weeks of study or any prior PEG-IFN therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Inquiry</last_name>
    <phone>415-654-5281</phone>
    <email>clinicaltrials@vir.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <state>Sha Tin</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chisinau</city>
        <zip>MD 2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10210</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10334</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Romania</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
  </removed_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>April 26, 2023</last_update_submitted>
  <last_update_submitted_qc>April 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Virus</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

